Literature DB >> 29299820

Malignant transformation in non-functioning pituitary adenomas (pituitary carcinoma).

Nèle Lenders1,2,3, Ann McCormack4,5.   

Abstract

Non-functioning pituitary carcinomas (NFPC) are defined as tumours of adenophyseal origin with craniospinal or systemic dissemination, with the absence of a hormonal hypersecretion syndrome. These are a histologically heterogenous group of tumours, comprising gonadotroph, null cell, "silent" tumours of corticotroph, somatotroph or lactotroph cell lineages as well as plurihormonal Pit-1 tumours. NFPC are exceedingly rare, and hence few cases have been described. This review has identified 38 patients with NFPC reported in the literature. Recurrent invasive non-functioning pituitary adenomas (NFPA) were observed in a majority of patients. Various factors have been identified as markers of the potential for aggressive behaviour, including rapid tumour growth, growth after radiotherapy, gain or shift of hormone secretion and raised proliferative markers. Typically, there is a latency of several years from the original presentation with an NFPA to identification of metastases and only 5 cases reported with rapidly progressive malignant disease within 1 month of presentation. Therapeutic options include debulking surgery, radiation therapy and chemotherapy with temozolomide recommended as first line systemic treatment. Although long-term survivors are described, prognosis remains generally very poor (median survival 8 months). Improvements in molecular tumour profiling may assist in predicting tumour behaviour, guide therapeutic choices and identify novel therapies.

Entities:  

Keywords:  Aggressive pituitary tumours; Metastases; Non-functioning pituitary adenomas; Pituitary carcinomas; Temozolomide

Mesh:

Substances:

Year:  2018        PMID: 29299820     DOI: 10.1007/s11102-017-0857-z

Source DB:  PubMed          Journal:  Pituitary        ISSN: 1386-341X            Impact factor:   4.107


  117 in total

Review 1.  Temozolomide responsiveness in aggressive corticotroph tumours: a case report and review of the literature.

Authors:  A K Annamalai; A F Dean; N Kandasamy; K Kovacs; H Burton; D J Halsall; A S Shaw; N M Antoun; H K Cheow; R W Kirollos; J D Pickard; H L Simpson; S J Jefferies; N G Burnet; M Gurnell
Journal:  Pituitary       Date:  2012-09       Impact factor: 4.107

2.  p53 expression in pituitary adenomas and carcinomas: correlation with invasiveness and tumor growth fractions.

Authors:  K Thapar; B W Scheithauer; K Kovacs; P J Pernicone; E R Laws
Journal:  Neurosurgery       Date:  1996-04       Impact factor: 4.654

3.  Letter to the editor.

Authors:  Kalman Kovacs; Fabio Rotondo; Eva Horvath; Luis V Syro; Antonio Di Ieva; Michael D Cusimano; David G Munoz
Journal:  Endocr Pathol       Date:  2015-03       Impact factor: 3.943

Review 4.  Somatostatin system: molecular mechanisms regulating anterior pituitary hormones.

Authors:  Tamar Eigler; Anat Ben-Shlomo
Journal:  J Mol Endocrinol       Date:  2014-04-29       Impact factor: 5.098

5.  A mechanism of acquiring temozolomide resistance during transformation of atypical prolactinoma into prolactin-producing pituitary carcinoma: case report.

Authors:  Mineko Murakami; Akiko Mizutani; Shuichiro Asano; Hideki Katakami; Yoshinori Ozawa; Kazuto Yamazaki; Yasuo Ishida; Koji Takano; Hiroko Okinaga; Akira Matsuno
Journal:  Neurosurgery       Date:  2011-06       Impact factor: 4.654

6.  SSTR3 is a putative target for the medical treatment of gonadotroph adenomas of the pituitary.

Authors:  Misu Lee; Amelie Lupp; Nigel Mendoza; Niamh Martin; Rudi Beschorner; Jürgen Honegger; Jürgen Schlegel; Talia Shively; Elke Pulz; Stefan Schulz; Federico Roncaroli; Natalia S Pellegata
Journal:  Endocr Relat Cancer       Date:  2014-12-16       Impact factor: 5.678

Review 7.  Pathohistological classification of pituitary tumors: 10 years of experience with the German Pituitary Tumor Registry.

Authors:  Wolfgang Saeger; Dieter K Lüdecke; Michael Buchfelder; Rudolf Fahlbusch; Hans-Jürgen Quabbe; Stephan Petersenn
Journal:  Eur J Endocrinol       Date:  2007-02       Impact factor: 6.664

8.  Prevalence of pituitary adenomas: a community-based, cross-sectional study in Banbury (Oxfordshire, UK).

Authors:  Alberto Fernandez; Niki Karavitaki; John A H Wass
Journal:  Clin Endocrinol (Oxf)       Date:  2009-07-24       Impact factor: 3.478

Review 9.  Genetic aspects of pituitary carcinoma: A systematic review.

Authors:  Zijiang Yang; Ting Zhang; Heng Gao
Journal:  Medicine (Baltimore)       Date:  2016-11       Impact factor: 1.889

10.  Histological criteria for atypical pituitary adenomas - data from the German pituitary adenoma registry suggests modifications.

Authors:  Christian P Miermeister; Stephan Petersenn; Michael Buchfelder; Rudolf Fahlbusch; Dieter K Lüdecke; Annett Hölsken; Markus Bergmann; Hans Ulrich Knappe; Volkmar H Hans; Jörg Flitsch; Wolfgang Saeger; Rolf Buslei
Journal:  Acta Neuropathol Commun       Date:  2015-08-19       Impact factor: 7.801

View more
  10 in total

1.  Lower all-cause mortality rates in patients harboring pituitary carcinoma following the introduction of temozolomide.

Authors:  Genya Aharon-Hananel; Ruth Percik; Muhamad Badarna; Inbal Uri; Amit Tirosh
Journal:  Endocrine       Date:  2019-07-02       Impact factor: 3.633

2.  Challenges in the Diagnosis of Pituitary Neuroendocrine Tumors.

Authors:  Sylvia L Asa
Journal:  Endocr Pathol       Date:  2021-04-17       Impact factor: 3.943

3.  Pituitary Carcinoma Diagnosis and Survival Improvement, with Affordable Care Act Correlation: A SEER Database Study.

Authors:  Nathan J Wallace; Anand K Devaiah
Journal:  J Neurol Surg B Skull Base       Date:  2021-02-04

4.  An Institutional Experience of Tumor Progression to Pituitary Carcinoma in a 15-Year Cohort of 1055 Consecutive Pituitary Neuroendocrine Tumors.

Authors:  Omalkhaire M Alshaikh; Sylvia L Asa; Ozgur Mete; Shereen Ezzat
Journal:  Endocr Pathol       Date:  2019-06       Impact factor: 3.943

5.  A Population-Level Analysis of Pituitary Carcinoma from the National Cancer Database.

Authors:  Ryan M Carey; Edward C Kuan; Alan D Workman; Neil N Patel; Michael A Kohanski; Charles C L Tong; Jinbo Chen; James N Palmer; Nithin D Adappa; Jason A Brant
Journal:  J Neurol Surg B Skull Base       Date:  2019-03-15

6.  Regulating the CCNB1 gene can affect cell proliferation and apoptosis in pituitary adenomas and activate epithelial-to-mesenchymal transition.

Authors:  Bin Li; Hai-Bo Zhu; Gui-Dong Song; Jian-Hua Cheng; Chu-Zhong Li; Ya-Zhuo Zhang; Peng Zhao
Journal:  Oncol Lett       Date:  2019-09-10       Impact factor: 2.967

Review 7.  An Update on Silent Corticotroph Adenomas: Diagnosis, Mechanisms, Clinical Features, and Management.

Authors:  Shenzhong Jiang; Xiaokun Chen; Yinzi Wu; Renzhi Wang; Xinjie Bao
Journal:  Cancers (Basel)       Date:  2021-12-06       Impact factor: 6.639

8.  Tamoxifen Exerts Anticancer Effects on Pituitary Adenoma Progression via Inducing Cell Apoptosis and Inhibiting Cell Migration.

Authors:  Tingting Lv; Zirui Zhang; Haoying Yu; Shuyue Ren; Jingrong Wang; Shang Li; Lan Sun
Journal:  Int J Mol Sci       Date:  2022-02-28       Impact factor: 5.923

9.  A common classification framework for neuroendocrine neoplasms: an International Agency for Research on Cancer (IARC) and World Health Organization (WHO) expert consensus proposal.

Authors:  Guido Rindi; David S Klimstra; Behnoush Abedi-Ardekani; Sylvia L Asa; Frederik T Bosman; Elisabeth Brambilla; Klaus J Busam; Ronald R de Krijger; Manfred Dietel; Adel K El-Naggar; Lynnette Fernandez-Cuesta; Günter Klöppel; W Glenn McCluggage; Holger Moch; Hiroko Ohgaki; Emad A Rakha; Nicholas S Reed; Brian A Rous; Hironobu Sasano; Aldo Scarpa; Jean-Yves Scoazec; William D Travis; Giovanni Tallini; Jacqueline Trouillas; J Han van Krieken; Ian A Cree
Journal:  Mod Pathol       Date:  2018-08-23       Impact factor: 7.842

10.  Phosphorylated EGFR (pEGFR T693) as a Novel Predictor of Recurrence in Non-Functioning Pituitary Adenomas.

Authors:  Ashutosh Rai; Liza Das; Kanchan K Mukherjee; Sivashanmugam Dhandapani; Manjul Tripathi; Chirag Kamal Ahuja; Bishan Dass Radotra; Pinaki Dutta
Journal:  Front Endocrinol (Lausanne)       Date:  2021-07-05       Impact factor: 5.555

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.